Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

NCT ID: NCT04999839

Last Updated: 2023-09-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 259 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-08-11
• Study Completion Date: 2022-09-12

Brief Summary

This is a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with moderate to severe plaque psoriasis. This study will also evaluate the plasma concentrations of NDI-034858 and explore the immune response to NDI-034858 in participants with moderate to severe plaque psoriasis.

Detailed Description

Approximately 259 male and female participants, aged 18 to 70 years (inclusive) were enrolled in this study. Participants were randomized to receive either one of the four doses of NDI-034858, or placebo on Day 1. The goal was to have approximately 50 participants randomized per treatment group (1:1:1:1:1 ratio) on Day 1. During the treatment period, NDI-034858 or placebo was orally administered QD for 12 weeks. The 12 week treatment period was followed by a 4-week safety follow-up period.

Conditions

Moderate to Severe Plaque Psoriasis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Participants received placebo matched to NDI-034858 oral capsules, once daily (QD) for up to 12 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo matched to NDI-034858 oral capsules.

NDI-034858 2 milligrams (mg)

Participants received 2 mg of NDI-034858 oral capsules, QD for up to 12 weeks.

Group Type: EXPERIMENTAL

NDI-034858 study drug

Intervention Type: DRUG

NDI-034858 2 mg oral capsules.

NDI-034858 5 mg

Participants received 5 mg of NDI-034858 oral capsules, QD for up to 12 weeks.

Group Type: EXPERIMENTAL

NDI-034858 study drug

Intervention Type: DRUG

NDI-034858 5 mg oral capsules.

NDI-034858 15 mg

Participants received 15 mg of NDI-034858 oral capsules, QD for up to 12 weeks.

Group Type: EXPERIMENTAL

NDI-034858 study drug

Intervention Type: DRUG

NDI-034858 15 mg oral capsules.

NDI-034858 30 mg

Participants received 30 mg (2\*15 mg) of NDI-034858 oral capsules, QD for up to 12 weeks.

Group Type: EXPERIMENTAL

NDI-034858 study drug

Intervention Type: DRUG

NDI-034858 30 mg (2\*15 mg) oral capsules.

Interventions

NDI-034858 study drug

NDI-034858 2 mg oral capsules.

Intervention Type: DRUG

NDI-034858 study drug

NDI-034858 5 mg oral capsules.

Intervention Type: DRUG

NDI-034858 study drug

NDI-034858 15 mg oral capsules.

Intervention Type: DRUG

NDI-034858 study drug

NDI-034858 30 mg (2\*15 mg) oral capsules.

Intervention Type: DRUG

Placebo

Placebo matched to NDI-034858 oral capsules.

Intervention Type: OTHER

Other Intervention Names

NDI-034858; TAK-279; NDI-034858; TAK-279; NDI-034858; TAK-279; NDI-034858; TAK-279; Non Active Ingredient

Eligibility Criteria

Inclusion Criteria

In order to be eligible to participate in this study, a participant must meet all of the following criteria, either at the screening and Day 1 visits or only at one of the specified visits (screening or Day 1) as noted in the criterion:

1. Male or female participant aged 18 to 70 years, inclusive, at the time of consent.

2. Participant has a history of plaque psoriasis for at least 6 months prior to the screening visit.

3. Participant had no significant flare in psoriasis for at least 3 months before screening (information obtained from medical chart or participant's physician, or directly from the participant).

4. Participant has moderate to severe plaque psoriasis as defined by a PASI score ≥ 12 and a PGA score ≥ 3 at screening and Day 1.

5. Participant has plaque psoriasis covering ≥ 10% of his or her total BSA at screening and Day 1.

6. Participant must be a candidate for phototherapy or systemic therapy.

7. For female participants of childbearing potential involved in any sexual intercourse that could lead to pregnancy: the participant must agree to use a highly effective contraceptive method from at least 4 weeks prior to Day 1 until at least 4 weeks after the last study product administration. Highly effective contraceptive methods include hormonal contraceptives (eg, combined oral contraceptive, patch, vaginal ring, injectable, or implant), intrauterine devices or intrauterine systems, vasectomized partner(s) (provided vasectomy was performed ≥ 4 months prior to screening), bilateral tubal ligation or occlusion, or double barrier methods of contraception (eg, male condom with cervical cap, male condom with diaphragm, and male condom with contraceptive sponge) in conjunction with spermicide.

8. Female participants of childbearing potential have had a negative serum pregnancy test at screening and negative urine pregnancy test at Day 1.

9. For male participants involved in any sexual intercourse that could lead to pregnancy, participant must agree to use one of the highly effective contraceptive methods listed in Inclusion Criterion 6, from Day 1 until at least 12 weeks after the last study product administration. If the female partner of a male participant uses any of the hormonal contraceptive methods listed above, this contraceptive method should be used by the female partner from at least 4 weeks before Day 1 until at least 12 weeks after the last study product administration.

10. Participant has a BMI within the range of 18 to 42 kg/m2, inclusive (BMI = weight [kg]/[height (m)]2), and total body weight >50 kg (110 lb).

11. Participant is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.

12. Participant must be willing to comply with all study procedures and must be available for the duration of the study.

Exclusion Criteria

A participant who meets any of the following criteria at the screening and/or Day 1 visits, as applicable, will be excluded from participation in this study:

1. Participant is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.

2. Participant has evidence of erythrodermic, pustular, predominantly guttate psoriasis, or drug induced psoriasis.

3. Participant has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.

4. Participant has immune-mediated conditions commonly associated with psoriasis, such as psoriatic arthritis, uveitis, inflammatory bowel disease, that require systemic treatment (including corticosteroids, immunosuppressants, or biologics). Note: Participants with immune-mediated conditions that do not require systemic treatment may be included in the study. Certain therapies such as NSAIDs may be permitted, but should be discussed with the Medical Monitor prior to determination of participant eligibility.

5. Participant has any clinically significant medical condition, evidence of an unstable clinical condition (eg, cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, immunologic, or local active infection/infectious illness), psychiatric condition, or vital signs/physical/laboratory/ECG abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results.

6. Participant had a major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study.

7. Participant has a history of Class III or IV congestive heart failure as defined by New York Heart Association Criteria.

8. Participant has been hospitalized in the past 3 months for asthma, has ever required intubation for treatment of asthma, currently require oral corticosteroids for the treatment of asthma, or has required more than one short-term (≤ 2 weeks) course of oral corticosteroids for asthma within 6 months prior to Day 1.

9. Participant has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Participant with successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded.

10. Participant has a history of fever, inflammation, or systemic signs of illness suggestive of systemic or invasive infection within 4 weeks prior to Day 1.

11. Participant has an active bacterial, viral, fungal, mycobacterial infection, or other infection (including TB or atypical mycobacterial disease), or any major episode of infection that required hospitalization or treatment with intravenous antibiotics within 12 weeks prior to Day 1, or oral antibiotics within 4 weeks prior to Day 1.

12. Participant has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection, recurrent urinary tract infection, fungal infection (with the exception of superficial fungal infection of the nailbed), or infected skin wounds or ulcers.

13. Participant has a history of an infected joint prosthesis or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced.

14. Participant has active herpes infection, including herpes simplex 1 and 2 and herpes zoster (demonstrated on physical examination and/or medical history) within 8 weeks prior to Day 1.

15. Participant has a history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status in the opinion of the investigator (eg, history of splenectomy, primary immunodeficiency).

16. Participant has positive results for hepatitis B surface antigens (HBsAg), antibodies to hepatitis B core antigens (anti-HBc), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).

17. Participant has clinical or laboratory evidence of active or latent TB infection at screening.

18. Participant with any of the following laboratory values at the screening visit:

1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values ≥ 3 times the upper limit of normal (ULN);

2. Hemoglobin < 11.0 g/dL (< 110.0 g/L);

3. White blood cell count < 3.5 x 109/L (< 3500/mm3);

4. Absolute neutrophil count of < 1.8 x 109/L (< 1800/mm3);

5. Absolute lymphocyte count of < 1.0 x 109/L (< 1000/mm3);

6. Platelet count < 100 x 109/L (< 100,000/mm3);

7. Total bilirubin ˃ 2 times the ULN.

19. Participant who have given > 50 ml of blood or plasma within 30 days of screening or > 500 mL of blood or plasma within 56 days of screening (during a clinical study or at a blood bank donation).

20. Participant has used any topical medication that could affect psoriasis (including corticosteroids, retinoids, vitamin D analogues [such as calcipotriol], JAK inhibitors, or tar) within 2 weeks prior to Day 1.

21. Participant has used any systemic treatment that could affect psoriasis (including oral, intravenous, intraarticular, intrathecal, intramuscular, or intralesional corticosteroids, oral retinoids, immunosuppressive/immunomodulating medication, methotrexate, cyclosporine, oral JAK inhibitors, or apremilast) within 4 weeks prior to Day 1.

22. Participant has received any UV-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1.

23. Participant has had PUVA treatment within 4 weeks prior to Day 1.

24. Participant has received any live-attenuated vaccine within 4 weeks prior to Day 1 or plans to receive a live-attenuated vaccine during the study and up to 4 weeks or 5 half lives of the study product, whichever is longer, after the last study product administration. Note: Nonlive-attenuated vaccines or boosters for Coronavirus Disease 2019 (COVID-19) (eg, RNA-based vaccines, inactivated adenovirus-based vaccines, protein-based vaccines) are allowed during the study. The study site should follow local guidelines related to COVID-19.

25. Participant is currently receiving a nonbiological investigational product or device or has received one within 4 weeks prior to Day 1.

26. Participant has received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1 (except those listed in Exclusion Criterion 27 and 28 that are to be excluded for 6 months).

27. Participant was previously enrolled in any study with NDI-034858.

28. Participant has a history of lack of response to any therapeutic agent targeting IL-12, IL-17, and/or IL 23 (eg, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, risankizumab) at approved doses after at least 12 weeks of therapy, and/or received one of these therapies within 6 months prior to Day 1.

29. Participant has received rituximab or other immune-cell depleting therapy within 6 months.

30. Participant is currently being treated with strong or moderate cytochrome P450 3A (CYP3A4) inhibitors (such as itraconazole), or has received moderate or strong CYP3A4 inhibitors within 4 weeks prior to Day 1.

31. Participant is currently being treated with terbinafine, or has received terbinafine within 4 weeks prior to Day 1.

32. Participant has consumed grapefruit within 1 week prior to Day 1.

33. Participant has used tanning booths within 4 weeks prior to Day 1, has had excessive sun exposure, or is not willing to minimize natural and artificial sunlight exposure during the study.

34. Participant has a known or suspected allergy to NDI-034858 or any component of the investigational product, or any other significant drug allergy (such as anaphylaxis or hepatotoxicity).

35. Participant has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1.

36. For participant consenting to biopsy collection only:

• Participant has a history of an allergic reaction or significant sensitivity to lidocaine or other local anesthetics.
• Participant has a history of hypertrophic scarring or keloid formation in scars or suture sites.
• Participant has taken anticoagulant medication, such as heparin, low molecular weight (LMW)-heparin, warfarin, or antiplatelet agents (except low-dose aspirin ≤ 81 mg which will be allowed), within 2 weeks prior to Day 1, or has a contraindication to skin biopsies. Nonsteroidal anti-inflammatory drugs will not be considered antiplatelet agents and will be allowed.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Innovaderm Research Inc.

OTHER

Sponsor Role: collaborator

Nimbus Lakshmi, Inc.

INDUSTRY

Sponsor Role: collaborator

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

Nimbus site 137

Birmingham, Alabama, United States

Nimbus site 156

Birmingham, Alabama, United States

Nimbus site 132

Scottsdale, Arizona, United States

Nimbus site 133

Bryant, Arkansas, United States

Nimbus site 134

Fountain Valley, California, United States

Nimbus site 108

Los Angeles, California, United States

Nimbus site 124

Sacramento, California, United States

Nimbus site 153

San Diego, California, United States

Nimbus site 111

San Diego, California, United States

Nimbus site 148

Santa Rosa, California, United States

Nimbus site 120

Sherman Oaks, California, United States

Nimbus site 155

Doral, Florida, United States

Nimbus site 149

Hialeah, Florida, United States

Nimbus site 130

Largo, Florida, United States

Nimbus site 160

Margate, Florida, United States

Nimbus site 107

Miami Lakes, Florida, United States

Nimbus site 139

Miami Lakes, Florida, United States

Nimbus site 118

Ocala, Florida, United States

Nimbus site 157

Sweetwater, Florida, United States

Nimbus site 101

Tampa, Florida, United States

Nimbus site 102

Tampa, Florida, United States

Nimbus site 116

West Palm Beach, Florida, United States

Nimbus site 147

Columbus, Georgia, United States

Nimbus site 150

Macon, Georgia, United States

Nimbus site 119

Sandy Springs, Georgia, United States

Nimbus site 123

Skokie, Illinois, United States

Nimbus site 159

Clarksville, Indiana, United States

Nimbus site 140

Indianapolis, Indiana, United States

Nimbus site 154

Overland Park, Kansas, United States

Nimbus site 161

Louisville, Kentucky, United States

Nimbus site 105

Louisville, Kentucky, United States

Nimbus site 136

Lake Charles, Louisiana, United States

Numbus site 114

Metairie, Louisiana, United States

Nimbus site 122

Rockville, Maryland, United States

Nimbus site 115

Beverly, Massachusetts, United States

Nimbus site 135

Quincy, Massachusetts, United States

Nimbus site 146

Ann Arbor, Michigan, United States

Nimbus site 103

Bay City, Michigan, United States

Nimbus site 112

Troy, Michigan, United States

Nimbus site 138

Troy, Michigan, United States

Nimbus site 158

New Brighton, Minnesota, United States

Nimbus site 143

New York, New York, United States

Nimbus site 129

Charlotte, North Carolina, United States

Nimbus site 106

Wilmington, North Carolina, United States

Nimbus site 127

Bexley, Ohio, United States

Nimbus site 145

Columbus, Ohio, United States

Nimbus site 128

Fairborn, Ohio, United States

Nimbus site 141

Norman, Oklahoma, United States

Nimbus site 125

Pittsburgh, Pennsylvania, United States

Nimbus site 110

Charleston, South Carolina, United States

Nimbus site 117

Jackson, Tennessee, United States

Nimbus site 121

Nashville, Tennessee, United States

Nimbus site 109

Arlington, Texas, United States

Nimbus site 113

Bellaire, Texas, United States

Nimbus site 131

Katy, Texas, United States

Nimbus site 104

San Antonio, Texas, United States

Nimbus site 152

San Antonio, Texas, United States

Nimbus site 162

Webster, Texas, United States

Nimbus site 142

Spokane, Washington, United States

Nimbus site 204

Calgary, , Canada

Nimbus site 206

Calgary, , Canada

Nimbus site 212

Edmonton, , Canada

Nimbus site 209

Hamilton, , Canada

Nimbus site 203

Markham, , Canada

Nimbus site 201

Montreal, , Canada

Nimbus site 205

Oshawa, , Canada

Nimbus site 210

Peterborough, , Canada

Nimbus site 208

Red Deer, , Canada

Nimbus site 202

Waterloo, , Canada

Countries

United States; Canada

References

Armstrong AW, Gooderham M, Lynde C, Maari C, Forman S, Green L, Laquer V, Zhang X, Franchimont N, Gangolli EA, Blau J, Zhao Y, Zhang W, Srivastava B, Heap G, Papp K. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial. JAMA Dermatol. 2024 Oct 1;160(10):1066-1074. doi: 10.1001/jamadermatol.2024.2701.

Reference Type: DERIVED

PMID: 39167366 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://clinicaltrials.takeda.com/study-detail/4b255e32353e400a

To obtain more information on the study, click here/on this link

Other Identifiers

4858-201

Identifier Type: -

Identifier Source: org_study_id